Research ArticleArticle
Open Access
COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
Baptiste Chevet, Gabriel Figueroa-Parra, Jeffrey X. Yang, Cassondra A. Hulshizer, Tina M. Gunderson, Stephanie Q. Duong, Michael S. Putman, Kamil E. Barbour, Cynthia S. Crowson and Alí Duarte-García
The Journal of Rheumatology July 2022, jrheum.220220; DOI: https://doi.org/10.3899/jrheum.220220
Baptiste Chevet
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Gabriel Figueroa-Parra
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Jeffrey X. Yang
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Cassondra A. Hulshizer
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Tina M. Gunderson
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Stephanie Q. Duong
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Michael S. Putman
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Kamil E. Barbour
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Cynthia S. Crowson
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Alí Duarte-García
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu. Accepted for publication June 17, 2022.
Article Information
jrheum.220220
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online September 15, 2022.
Article Versions
- Latest version (July 1, 2022 - 04:00).
- You are currently viewing a Latest version of this article (September 15, 2022 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2022 The Journal of Rheumatology
Author Information
- Baptiste Chevet,
- Gabriel Figueroa-Parra,
- Jeffrey X. Yang,
- Cassondra A. Hulshizer,
- Tina M. Gunderson,
- Stephanie Q. Duong,
- Michael S. Putman,
- Kamil E. Barbour,
- Cynthia S. Crowson and
- Alí Duarte-García
- The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH.
B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA.
B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors.
The authors declare no conflicts of interest relevant to this article.
Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali@mayo.edu.
Accepted for publication June 17, 2022.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
Baptiste Chevet, Gabriel Figueroa-Parra, Jeffrey X. Yang, Cassondra A. Hulshizer, Tina M. Gunderson, Stephanie Q. Duong, Michael S. Putman, Kamil E. Barbour, Cynthia S. Crowson, Alí Duarte-García
The Journal of Rheumatology Jul 2022, jrheum.220220; DOI: 10.3899/jrheum.220220
COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
Baptiste Chevet, Gabriel Figueroa-Parra, Jeffrey X. Yang, Cassondra A. Hulshizer, Tina M. Gunderson, Stephanie Q. Duong, Michael S. Putman, Kamil E. Barbour, Cynthia S. Crowson, Alí Duarte-García
The Journal of Rheumatology Jul 2022, jrheum.220220; DOI: 10.3899/jrheum.220220